Mitralklappenendokardiose und DCM – Staging, Diagnostik und Therapie

Wussten Sie, dass 10% Ihrer Hundepatienten an einer progressiven Herzerkrankung leiden? Und wie der Weg zu einer raschen Diagnose und Therapie aussieht? Hier lesen Sie alles, was dazu im Praxisalltag wichtig ist.

• Literatur

• 1 Atkins C. et al.. ACVIM consensus statement: guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009; 23: 1142
• 2 Boswood A. et al.. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC study- a randomized clinical trial. J Vet Intern Med 2016; 30: 1765-1779
• 3 Häggström J. et al.. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: The QUEST study. J Vet Intern Med 2008; 22: 1124-1135
• 4 Lombard C. et al.. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006; 42: 249-261
• 5 Smith P. et al.. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract 2005; 46: 121-130
• 6 Summerfield NJ. et al.. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study). J Vet Intern Med 2012; 26 (06) 1337-1349
• 7 Fuentes L. et al.. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med 2002; 16: 255
• 8 OʼGrady MR. et al.. Effect of pimobendan on case fatality rate in Doberman pinschers with congestive heart failure caused by dilated cardiomyopathy. J Vet Intern Med 2008; 22: 897
• 9 Borgarelli M. et al.. Prognostic indicators for dogs with dilated cardiomyopathy. J Vet Intern Med 2006; 20: 104